Angiodynamics (ANGO) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Angiodynamics (ANGO) over the last 17 years, with Q4 2025 value amounting to 7.71%.
- Angiodynamics' EBIT Margin rose 75200.0% to 7.71% in Q4 2025 from the same period last year, while for Nov 2025 it was 10.59%, marking a year-over-year increase of 726700.0%. This contributed to the annual value of 13.66% for FY2025, which is 496600.0% up from last year.
- According to the latest figures from Q4 2025, Angiodynamics' EBIT Margin is 7.71%, which was up 75200.0% from 14.07% recorded in Q3 2025.
- Angiodynamics' EBIT Margin's 5-year high stood at 44.52% during Q3 2023, with a 5-year trough of 265.88% in Q1 2024.
- For the 5-year period, Angiodynamics' EBIT Margin averaged around 23.25%, with its median value being 12.47% (2021).
- Per our database at Business Quant, Angiodynamics' EBIT Margin plummeted by -2548200bps in 2024 and then skyrocketed by 2520300bps in 2025.
- Angiodynamics' EBIT Margin (Quarter) stood at 11.09% in 2021, then increased by 14bps to 9.5% in 2022, then tumbled by -75bps to 16.59% in 2023, then grew by 8bps to 15.23% in 2024, then surged by 49bps to 7.71% in 2025.
- Its EBIT Margin stands at 7.71% for Q4 2025, versus 14.07% for Q3 2025 and 7.22% for Q2 2025.